What is Idera Pharmaceuticals, Inc. (IDRA) stock price today?

Idera Pharmaceuticals, Inc. (IDRA) is currently trading at $0.43, down 21.82% today.

What is IDRA P/E ratio?

Idera Pharmaceuticals, Inc.'s P/E ratio is -0.06. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is IDRA return on equity (ROE)?

Idera Pharmaceuticals, Inc.'s return on equity (ROE) is -191.67%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

NASDAQ · Biotechnology

Idera Pharmaceuticals, Inc. (IDRA) Stock

$0.43 -21.82% NASDAQ: IDRA Healthcare

Idera Pharmaceuticals, Inc. is a biopharmaceutical company committed to the research, development, and commercialization of medicines addressing rare diseases within the United States.

Valuation

Metric	Value
Price	$0.43
Market Cap	$0
P/E Ratio	-0.06
P/B Ratio	0.12
P/S Ratio	0.00
EPS (TTM)	$-7.18
52-Week High	$16.00
52-Week Low	$0.42
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-191.67%
ROA	-22.77%
ROCE	-34.91%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.08
Current Ratio	0.86

Annual Financials (USD)

Metric	2018	2019	2020	2021	2022
Revenue	$1.0M	$1.0M	$0	$0	$0
Operating Profit	$-61.0M	$-46.0M	$-37.0M	$-28.0M	$-28.0M
Net Profit	$-60.0M	$-85.0M	$-113.0M	$98.0M	$-23.0M
EPS	$-38.27	$-33.66	$-56.63	$31.55	$-7.18
Op Margin	-9207.9%	-3181.4%	—	—	—

Balance Sheet (USD)

Metric	2018	2019	2020	2021	2022
Total Assets	$73.0M	$47.0M	$42.0M	$35.0M	$101.0M
Total Liabilities	$9.0M	$59.0M	$134.0M	$5.0M	$62.0M
Cash	$71.0M	$40.0M	$33.0M	$33.0M	$12.0M
Borrowings	$0	$1.0M	$1.0M	$1.0M	$1.0M

Cash Flow (USD)

Metric	2018	2019	2020	2021	2022
Operating Cash Flow	$-52.0M	$-44.0M	$-34.0M	$-25.0M	$-24.0M
Investing Cash Flow	$0	$-2.0M	$-2.0M	$5.0M	$5.0M
Financing Cash Flow	$10.0M	$15.0M	$29.0M	$19.0M	$-1.0M
Net Cash Flow	$-42.0M	$-31.0M	$-7.0M	$-1.0M	$-21.0M
Free Cash Flow	$-52.0M	$-45.0M	$-34.0M	$-25.0M	$-24.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.41
FCF Yield	—
Quick Ratio	0.83
Interest Coverage	-136.36
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALLKAllakos Inc.	$0.33	+0.22%	-0.25	$29.74M	0.00%
ANGNAngion Biomedica Corp.	$1.00	+0.00%	-0.42	$30.11M	0.00%
ANPCAnPac Bio-Medical Science Co., Ltd.	$4.30	-3.15%	-0.54	$26.97M	0.00%
FRLNFreeline Therapeutics Holdings plc	$6.49	+0.15%	-0.29	$28.28M	0.00%
GMTXGemini Therapeutics, Inc.	$1.35	+0.00%	-0.22	$25.49M	0.00%

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc. is a biopharmaceutical company committed to the research, development, and commercialization of medicines addressing rare diseases within the United States. A key offering is Tilsotolimod (IMO-2125), a proprietary synthetic phosphorothioate oligonucleotide. This compound functions as a direct TLR9 agonist, designed to stimulate the immune system to combat solid tumors, specifically targeting head and neck squamous cell carcinoma and colorectal cancer. The firm also holds a strategic collaboration agreement with Bristol-Myers Squibb. Founded in 1989, Idera Pharmaceuticals, Inc. is headquartered in Exton, Pennsylvania.

the stock is valued at a price-to-earnings (P/E) ratio of -0.06, price-to-book of 0.12, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.42 and $16.00, and currently trades 97.3% below its 52-week high.

On profitability, Idera Pharmaceuticals, Inc. generates a return on equity (ROE) of -191.67%, return on capital employed of -34.91%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.iderapharma.com